BR0015195A - Composto, composição farmacêutica, uso de um composto, e, métodos para o tratamento de uma condição associada com a transmissão reduzida de nicotina para o tratamento ou profilaxia de distúrbios psicóticos ou distúrbios de deterioração intelectual e para o tratamento ou profilaxia de doenças ou condições humanas - Google Patents

Composto, composição farmacêutica, uso de um composto, e, métodos para o tratamento de uma condição associada com a transmissão reduzida de nicotina para o tratamento ou profilaxia de distúrbios psicóticos ou distúrbios de deterioração intelectual e para o tratamento ou profilaxia de doenças ou condições humanas

Info

Publication number
BR0015195A
BR0015195A BR0015195-5A BR0015195A BR0015195A BR 0015195 A BR0015195 A BR 0015195A BR 0015195 A BR0015195 A BR 0015195A BR 0015195 A BR0015195 A BR 0015195A
Authority
BR
Brazil
Prior art keywords
compound
alkyl
treatment
prophylaxis
hydrogen
Prior art date
Application number
BR0015195-5A
Other languages
English (en)
Portuguese (pt)
Inventor
David Gurley
Thomas Lanthorn
John Macor
James Rosamond
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of BR0015195A publication Critical patent/BR0015195A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Addiction (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
BR0015195-5A 1999-11-03 2000-11-01 Composto, composição farmacêutica, uso de um composto, e, métodos para o tratamento de uma condição associada com a transmissão reduzida de nicotina para o tratamento ou profilaxia de distúrbios psicóticos ou distúrbios de deterioração intelectual e para o tratamento ou profilaxia de doenças ou condições humanas BR0015195A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9903997A SE9903997D0 (sv) 1999-11-03 1999-11-03 New compounds
PCT/SE2000/002148 WO2001032619A1 (en) 1999-11-03 2000-11-01 Positive modulators of nicotinic receptor agonists

Publications (1)

Publication Number Publication Date
BR0015195A true BR0015195A (pt) 2002-06-18

Family

ID=20417607

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0015195-5A BR0015195A (pt) 1999-11-03 2000-11-01 Composto, composição farmacêutica, uso de um composto, e, métodos para o tratamento de uma condição associada com a transmissão reduzida de nicotina para o tratamento ou profilaxia de distúrbios psicóticos ou distúrbios de deterioração intelectual e para o tratamento ou profilaxia de doenças ou condições humanas

Country Status (16)

Country Link
US (1) US6750242B1 (enExample)
EP (1) EP1230216A1 (enExample)
JP (1) JP2003513071A (enExample)
KR (1) KR20020063176A (enExample)
CN (1) CN1239482C (enExample)
AU (1) AU783507B2 (enExample)
BR (1) BR0015195A (enExample)
CA (1) CA2387745A1 (enExample)
CO (1) CO5251458A1 (enExample)
IL (1) IL149098A0 (enExample)
MX (1) MXPA02004232A (enExample)
NO (1) NO323076B1 (enExample)
NZ (2) NZ518450A (enExample)
SE (1) SE9903997D0 (enExample)
WO (1) WO2001032619A1 (enExample)
ZA (1) ZA200203171B (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9903998D0 (sv) * 1999-11-03 1999-11-03 Astra Ab New compounds
DE10164139A1 (de) 2001-12-27 2003-07-10 Bayer Ag 2-Heteroarylcarbonsäureamide
DE10234424A1 (de) * 2002-07-29 2004-02-12 Bayer Ag Benzothiophen-, Benzofuran- und Indolharnstoffe
US7244745B2 (en) 2002-08-30 2007-07-17 Memory Pharmaceuticals Corp. Heterocyclic compounds, methods for the preparation thereof, and uses thereof
CA2499128C (en) 2002-09-25 2012-07-31 Memory Pharmaceuticals Corporation Indazoles, benzothiazoles, and benzoisothiazoles, and preparation and uses thereof
WO2005092890A2 (en) 2004-03-25 2005-10-06 Memory Pharmaceuticals Corporation Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, and preparation and uses thereof
ATE489138T1 (de) 2005-04-13 2010-12-15 Neuraxon Inc Substituierte indolverbindungen mit nos-hemmender aktivität
US20070134169A1 (en) * 2005-12-11 2007-06-14 Rabinoff Michael D Methods for smoking cessation or alcohol cessation or other addiction cessation
ZA200809659B (en) * 2006-04-13 2010-03-31 Neuraxon Inc 1,5 and 3,6-substituted indole compounds having NOS inhibitory activity
WO2009062318A1 (en) * 2007-11-16 2009-05-22 Neuraxon, Inc. 3,5-substituted indole compounds having nos and norepinephrine reuptake inhibitory activity
US20090163451A1 (en) * 2007-11-16 2009-06-25 Frank Porreca Methods for treating visceral pain
EA201000808A1 (ru) * 2007-11-16 2011-04-29 Ньюраксон, Инк. Индольные соединения и способы лечения висцеральной боли
US8383657B2 (en) 2007-12-21 2013-02-26 Abbott Laboratories Thiazolylidine urea and amide derivatives and methods of use thereof
US8536221B2 (en) * 2008-02-07 2013-09-17 Abbvie Inc. Amide derivatives as positive allosteric modulators and methods of use thereof
ES2392796T3 (es) * 2008-04-17 2012-12-13 Proximagen Limited Moduladores de tipo indol del receptor nicotínico de acetilcolina alfa-7
EA019518B1 (ru) * 2009-04-16 2014-04-30 Проксимаген Лимитед ПРОИЗВОДНЫЕ ИНДОЛА В КАЧЕСТВЕ МОДУЛЯТОРОВ РЕЦЕПТОРА α7 nAChR
TWI519532B (zh) * 2010-05-17 2016-02-01 艾維沃製藥公司 (R)-7-氯-N-(啶-3-基)苯並[b]噻吩-2-羧醯胺鹽酸鹽單水合物之結晶形體
TW201245185A (en) 2011-04-01 2012-11-16 Lundbeck & Co As H New positive allosteric modulators of nicotinic acetylcholine receptor
AR086791A1 (es) 2011-07-01 2014-01-22 Lundbeck & Co As H Moduladores alostericos positivos del receptor de acetilcolina nicotinico
RU2017136693A (ru) 2012-05-08 2019-02-08 Форум Фармасьютикалз, Инк. Способы поддержания, лечения или улучшения когнитивной функции
KR102242658B1 (ko) * 2018-08-29 2021-04-21 숙명여자대학교산학협력단 치환된 인돌 유도체, 이의 제조방법 및 이를 유효성분으로 포함하는 PPARα, PPARγ 및 PPARδ 관련 질환의 예방 또는 치료용 약학적 조성물

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2787551A (en) * 1954-02-24 1957-04-02 Eastman Kodak Co Compositions stabilized with hydroxyindole
BE758766A (fr) * 1969-11-17 1971-05-10 Ici Ltd Nouveaux derives de la morpholine et de la
US4704390A (en) * 1986-02-13 1987-11-03 Warner-Lambert Company Phenyl and heterocyclic tetrahydropyridyl alkoxy-benzheterocyclic compounds as antipsychotic agents
JPH06500551A (ja) * 1990-09-13 1994-01-20 ビーチャム・グループ・パブリック・リミテッド・カンパニー 5ht受容体アンタゴニストとしてのインドールウレア
CA2124206C (en) * 1991-11-25 2001-02-27 John Eugene Macor Indole derivatives
WO1993018026A1 (en) * 1992-03-04 1993-09-16 Beecham Group Plc Indole ureas as 5-ht1c receptor antogonists
US5504101A (en) * 1994-05-06 1996-04-02 Allelix Biopharmaceuticals, Inc. 5-HT-1D receptor ligands
FR2722686B1 (fr) * 1994-07-22 1996-08-30 Oreal Set, procede, dispositif et composition de teinture des fibres keratiniques
US5576321A (en) * 1995-01-17 1996-11-19 Eli Lilly And Company Compounds having effects on serotonin-related systems

Also Published As

Publication number Publication date
EP1230216A1 (en) 2002-08-14
NZ518450A (en) 2004-04-30
AU1426401A (en) 2001-05-14
NO20022009L (no) 2002-07-02
CO5251458A1 (es) 2003-02-28
NO323076B1 (no) 2006-12-27
AU783507B2 (en) 2005-11-03
CA2387745A1 (en) 2001-05-10
US6750242B1 (en) 2004-06-15
MXPA02004232A (es) 2002-10-17
SE9903997D0 (sv) 1999-11-03
IL149098A0 (en) 2002-11-10
ZA200203171B (en) 2003-09-23
KR20020063176A (ko) 2002-08-01
CN1239482C (zh) 2006-02-01
NO20022009D0 (no) 2002-04-26
WO2001032619A1 (en) 2001-05-10
JP2003513071A (ja) 2003-04-08
CN1387512A (zh) 2002-12-25
NZ530161A (en) 2005-08-26

Similar Documents

Publication Publication Date Title
BR0015193A (pt) Composto, composição farmacêutica, uso de um composto, e, método para tratamento de uma condição associada com trasmissão reduzida de nicotina, para tratamento ou profilaxia de distúrbios psicóticos ou distúrbios de deterioração intelectual e para tratamento ou profilaxia de doenças ou condições humanas
YU49443B (sh) Derivati benzimidazola, postupci za njihovo pripremanje i primena tih derivata u medicinskoj terapiji, naročito za lečenje ili sprečavanje virusnih infekcija
MY132872A (en) Benzimidazole derivatives.
DK1487829T3 (da) Thiadizolylpiperazinderivater, der er nyttige til behandling eller forebyggelse af smerte
BR9810924A (pt) Composto heterocìclico espiroazabicìclico, composição farmacêutica, uso de um composto, e, processos de tratamento ou profilaxia de doenças humanas ou condições em que a ativação do receptor nicotìnico alfa7 seja benéfica, de distúrbios psicóticos ou distúrbios do enfraquecimento intelectual e do desequilìbrio do ritmo circadiano normal devido a viagens subsÈnicas ou supersÈnicas, da cessação de fumar, do vìcio da nicotina, da dor e da colite ulcerativa e de preparação de um composto
DE60010076D1 (de) Chinolinderivate als antibakterielle mittel
HUP0001062A2 (hu) NAALADáz gátló hatású foszfinsavszármazékokat tartalmazó gyógyászati készítmények
DK0958296T3 (da) Heterocykliske forbindelser, fremgangsmåde til deres fremstilling og farmaceutiske præparater, der indeholder dem, og deres anvendelse i behandlingen af diabetes og beslægtede sygdomme
BR9812046A (pt) Compostos, processos para a preperação do composto e para tratar um paciente humano ou animal, composição farmacêutica, e, uso de um composto
BR0108456A (pt) Composto, uso de um composto, métodos de tratamento ou de profilaxia de distúrbios psicóticos ou distúrbios de deterioração intelectual e de doenças humanas, e ,processo para preparação de um composto
BR9912729A (pt) Derivado de amida, processo para prepará-lo, e, uso do mesmo
ATE273958T1 (de) Heterocyclische verbindungen als h+-atpasen
DE69930926D1 (de) Benzolsulfonamid-derivate und ihre anwendung als arzneimittel
BR0113448A (pt) Composto da fórmula ou um sal ou solvato deste ou um derivado destes fisiologicamente funcional, composição farmacêutica, uso do composto ou de um sal ou solvato deste ou de um derivado destes fisiologicamente funcional, e , métodos para tratar uma condição ou estado de doença mediados pela p38 quinase ou mediados pelas citoquinas, e mediados pela jnk quinase ou mediados pelas citoquinas, e ,para tratar duas ou mais condições ou doenças independentemente mediadas pela atividade da p38 e da jnk quinase
HUP0101999A2 (hu) 4-Hidroxi-kinolin-3-karboxamid- és -hidrazid-származékok, ezeket tartalmazó gyógyászati készítmények, valamint e vegyületek alkalmazása
MXPA01004256A (es) N-arilamidas del acido antranilico y del acido tioantranilico.
BR0010476A (pt) Compostos derivados do 4,5,6,7-tetrahidroindazol e seu uso como agentes antitumorais
UA44254C2 (uk) Похідні 4-(заміщеного феніламіно)хіназоліну, спосіб їх одержання, спосіб лікування і фармацевтична композиція
NO933452D0 (no) Et terapeutisk middel for parkinson's sykdom
BR0311541A (pt) indol, azaindol e 4-aquenil piperidina amidas heterocìclicas relacionadas
FI870421A0 (fi) Analogiamenetelmä alkueläintenvastaisesti vaikuttavien 5,6-dihydro-2-(substituoitu fenyyli)-1,2,4-triatsiini-3,5(2H,4H)-dionijohdannaisten valmistamiseksi
BR9807950A (pt) Composto, composição farmacêutica, uso de um composto, e, processos para tratar ou reduzir o risco de doenças ou condições humanas, o risco de doença inflamatória o risco da dor e para a preparação de um composto
BR0317680A (pt) Composto, composição farmacêutica, uso de um composto, ou de um sal farmaceuticamente aceitável do mesmo, método de tratamento de um ser humano, e, processo para a preparação de um composto
SE9903997D0 (sv) New compounds
NO882334D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive alkansulfonanilid-derivater.

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 DA RPI 2008 DE 30/06/2009.